Feasibility of 3D US/CEUS-US/CEUS fusion imaging-based ablation planning in liver tumors: a retrospective study

• Published in: Abdominal imaging Vol. 46; no. 6; pp. 2865 - 2874
• Main Authors: You, Yujia, Zhang, Man, Li, Kai, Zeng, Qingjing, Luo, Liping, Long, Yinglin, Tan, Lei, He, Xuqi, Liang, Ping, Xu, Erjiao, Zheng, Rongqin
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2021; Springer Nature B.V
• Subjects: Ablation; Ablative materials; Cholangiocarcinoma; Complications; Computed tomography; Diameters; Evaluation; Feasibility studies; Gastroenterology; Hepatobiliary; Hepatology; Imaging; Liver; Liver cancer; Magnetic resonance imaging; Medical imaging; Medicine; Medicine & Public Health; Planning; Radiology; Real time; Success; Tumors; Ultrasonic imaging; Ultrasound; United States > US; Fusion imaging; Thermal ablation; Liver cancer; Planning; Ultrasound
• ISSN: 2366-004X; 2366-0058
• DOI: 10.1007/s00261-020-02909-5

Purpose To assess the feasibility of ablation planning based on fusion imaging of three-dimensional ultrasound/contrast-enhanced ultrasound (3D US/CEUS) with real-time US/CEUS for liver tumor thermal ablation. Materials and methods Between January 2017 and December 2018, 85 hepatic tumors from 82 patients who underwent percutaneous ablation were included. First, intraprocedural 3D US/CEUS imaging was performed for ablation planning. Then, fusion imaging of 3D US/CEUS with real-time US/CEUS was used to guide the implementation of the plan, immediately evaluate the technical success and indicate the need for supplemental ablation. In addition, contrast-enhanced CT/MR imaging was performed 1 month after the procedure to evaluate the presence of residual tumors, and follow-up scans were repeated every 3 months. Results The average liver tumor diameter was 28 ± 9 mm (range, 10–55 mm). 3D US/CEUS-based planning was successfully conducted in all 85 tumors with a 100% technical success rate of planning. The immediate evaluation by 3D CEUS/US-CEUS fusion imaging showed a 100% technical success rate of ablation. The 1-month CT/MR scans found a residual tumor in one intrahepatic cholangiocarcinoma patient; the technique efficacy rate was 98.8%. The median follow-up period was 21.5 months (IQR: 4–36 months). During the follow-up period, the local tumor progression rate was 5.9% (5/84), and no major procedure-related complications occurred. Conclusions Ablation planning based on 3D US/CEUS-US/CEUS fusion imaging is feasible for liver tumors.